Segurança garantida e eficácia do teste rápido Lepu SARS-CoV-2 Antigen
-
2021-06-16
-
LEPU
Caro Cliente,
We are pleased to share with you the most updated news about our SARS-CoV-2 Teste Rápido Antigen: Market performance follow-up studies have confirmed the safety and effectiveness of Lepu SARS-CoV-2 Antigen Rapid test.
Para acompanhar e verificar continuamente o desempenho do teste rápido SARS-CoV-2 Antigen, a LEPU Medical Technology realizou vários estudos de acompanhamento de desempenho pós-mercado na Alemanha após obter a aprovação do BfArM para autoteste.
The post market performance follow-up studies include the performance for layman and professionals respectively. The diagnostic sensitivity was 91.30%, and the specificity was 100% in the study done by Biomex in April 2021. The diagnostic sensitivity was 95.90%, and the specificity was 100% in the study done by Biomex in June 2021. The test results were both acceptable for layman and professionals.
A Lepu fornecerá constantemente produtos inovadores e de alta qualidade para continuar atendendo às necessidades médicas globais. Sinta por favor livre deixar-me saber se você tem quaisquer perguntas. Obrigado.
Gentis cumprimentos,
Lepu Medical 
en.lepumedical.com
Follow us on social media
